Vanguard Group Inc Abeona Therapeutics Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,507,023 shares of ABEO stock, worth $16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,507,023

Previous 2,020,185 24.1%

Holding current value

$16 Million

Previous $9.62 Million 48.08%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$4.18 - $7.0 $2.03 Million - $3.41 Million	486,838 Added 24.1%	2,507,023 $14.2 Million
Q1 2025 May 09, 2025	BUY	$4.76 - $6.02 $257,811 - $326,055	54,162 Added 2.75%	2,020,185 $9.62 Million
Q4 2024 Feb 11, 2025	SELL	$5.55 - $6.67 $230,896 - $277,492	-41,603 Reduced 2.07%	1,966,023 $10.9 Million
Q3 2024 Nov 13, 2024	BUY	$4.12 - $6.32 $222,995 - $342,070	54,125 Added 2.77%	2,007,626 $12.7 Million
Q2 2024 Aug 13, 2024	BUY	$3.17 - $8.05 $2.7 Million - $6.85 Million	851,543 Added 77.28%	1,953,501 $8.28 Million
Q1 2024 May 10, 2024	BUY	$4.07 - $8.68 $3,365 - $7,178	827 Added 0.08%	1,101,958 $7.99 Million
Q4 2023 Feb 14, 2024	BUY	$3.71 - $5.14 $1.29 Million - $1.79 Million	348,196 Added 46.25%	1,101,131 $5.52 Million
Q3 2023 Nov 14, 2023	BUY	$2.98 - $4.43 $248,329 - $369,160	83,332 Added 12.44%	752,935 $3.17 Million
Q2 2023 Aug 14, 2023	BUY	$2.76 - $5.27 $583,083 - $1.11 Million	211,262 Added 46.09%	669,603 $2.7 Million
Q1 2023 May 15, 2023	BUY	$2.25 - $3.27 $373,074 - $542,201	165,811 Added 56.68%	458,341 $1.29 Million
Q4 2022 Feb 10, 2023	BUY	$2.4 - $5.65 $201 - $474	84 Added 0.03%	292,530 $900,000
Q3 2022 Nov 14, 2022	BUY	$2.79 - $5.56 $815,924 - $1.63 Million	292,446 New	292,446 $889,000

Others Institutions Holding ABEO

# of Institutions

Shares Held

29.7M

Call Options Held

2.34M

Put Options Held

198K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $38M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Abeona Therapeutics Inc. Transaction History